References
- Oberfeld B, Achanta A, Carpenter K, et al. SnapShot: COVID-19. Cell. 2020;181:954–954.e1.
- Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–452.
- Fan W, Su Z, Bin Y, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269. DOI:https://doi.org/10.1038/s41586-020-2008-3.
- Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
- Wang H, Li X, Li T, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis. 2020;1:1–7.
- Feehan J, Apostolopoulos V. Is COVID-19 the worst pandemic?. Maturitas. 2021;149:56–58.
- Hossain MK, Hassanzadeganroudsari M, Feehan J, et al. COVID-19 vaccines in the pipeline, are antibodies adequate?. Ed.^(Eds) Multidisciplinary Digital Publishing Institute; 2021.
- Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. 2020;579(7798):270–273.
- Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;102433.
- Lam TT-Y, Shum M-H-H, Zhu H-C, et al. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. BioRxiv. 2020.
- Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269.
- Coronavirus Disease. COVID-19. Situation Report 48; 2019. Accessed15 March 2021. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200308-sitrep-48-covid-19.pdf?sfvrsn=16f7ccef_4
- Zhu N, Zhang D, Wang W. China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019 [published January 24, 2020]. N Engl J Med. 2020;382:727–733.
- De Wit E, Van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nature Rev Microbiol. 2016;14(8):523.
- Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–76.
- COVID-19 coronavirus pandemic. [cited 2020 Sep 24]. https://www.worldometers.info/coronavirus
- Hossain MK, Hassanzadeganroudsari M, Apostolopoulos V. Why METH users are at high risk of fatality due to COVID-19 infection?. Ed.^(Eds) Taylor & Francis; 2020.
- Pak A, Adegboye OA, Adekunle AI, et al. Economic consequences of the COVID-19 outbreak: the need for epidemic preparedness. Front Public Health. 2020;8. DOI:https://doi.org/10.3389/fpubh.2020.00241
- Ozili PK, Arun T. Spillover of COVID-19: impact on the global economy. Available SSRN. 2020;3562570.
- Saladino V, Algeri D, Auriemma V. The psychological and social impact of Covid-19: new perspectives of well-being. Front Psychol. 2020;11:2550.
- Saddik B, Hussein A, Albanna A, et al. The psychological impact of the COVID-19 pandemic on adults and children in the United Arab Emirates: a nationwide cross-sectional study. BMC Psychiatry. 2021;21(1):1–18. DOI:https://doi.org/10.1186/s12888-021-03213-2.
- Temsah M-H, Al Huzaimi A, Alrabiaah A, et al. Changes in healthcare workers’ knowledge, attitudes, practices, and stress during the COVID-19 pandemic. Medicine (Baltimore). 2021;100(18):e25825. DOI:https://doi.org/10.1097/MD.0000000000025825.
- Batais MA, Temsah M-H, AlGhofili H, et al. The coronavirus disease of 2019 pandemic-associated stress among medical students in Middle East respiratory syndrome-CoV endemic area: an observational study. Medicine (Baltimore). 2021;100(3):e23690. DOI:https://doi.org/10.1097/MD.0000000000023690.
- Adibi A, Golitaleb M, Farrahi-Ashtiani I, et al. The prevalence of generalized anxiety disorder among health care workers during the COVID-19 pandemic: a systematic review and meta-analysis. Front Psychiatry. 2021;12. DOI:https://doi.org/10.3389/fpsyt.2021.658846.
- Temsah M-H, Barry M, Aljamaan F, et al. SARS-CoV-2 B. 1.1. 7 UK variant of concern lineage-related perceptions, COVID-19 vaccine acceptance and travel worry among healthcare workers. Front Public Health. 2021;9:617.
- Temsah M-H, Al-Sohime F, Alamro N, et al. The psychological impact of COVID-19 pandemic on health care workers in a MERS-CoV endemic country. J Infect Public Health. 2020;13(6):877–882. DOI:https://doi.org/10.1016/j.jiph.2020.05.021.
- Li LZ, Wang S. Prevalence and predictors of general psychiatric disorders and loneliness during COVID-19 in the United Kingdom. Psychiatry Res. 2020;291:113267.
- Cao W, Fang Z, Hou G, et al. The psychological impact of the COVID-19 epidemic on college students in China. Psychiatry Res. 2020;287:112934.
- Calina D, Docea AO, Petrakis D, et al. Towards effective COVID‑19 vaccines: updates, perspectives and challenges. Int J Mol Med. 2020;46(1):3–16. DOI:https://doi.org/10.3892/ijmm.2020.4596.
- Banerjee D. The impact of Covid‐19 pandemic on elderly mental health. Int J Geriatr Psychiatry. 2020;35:1466–1467.
- Lee N, McGeer A. The starting line for COVID-19 vaccine development. Lancet. 2020;395:1815–1816.
- Rismanbaf A. Potential treatments for COVID-19; a narrative literature review. Arch Acad Emergency Med. 2020. 8(1)
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578.
- FDA news release. Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment; May 2020. Accessed 30 January 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment
- Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clinl Infect Dis. 2020.
- Martin JH, Bowden NA. Drug repurposing in the era of COVID–a market failure needing leadership and government investment. Med J Aust. 2020;212(10):450–452.
- Horby P. NIH Covid-19 treatment guidelines; 2020. adapted)[8].
- Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Trans R Soc B. 2014;369(1645):20130433.
- Sharpe HR, Gilbride C, Allen E, et al. The early landscape of COVID‐19 vaccine development in the UK and rest of the world. Immunology. 2020;160:223–232.
- Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52:583–589.
- Hossain MK, Hassanzadeganroudsari M, Apostolopoulos V. The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines? Expert Rev Vaccines. 2021;1–4.
- Abdulla ZA, Al-Bashir SM, Al-Salih NS, et al. A summary of the SARS-CoV-2 vaccines and technologies available or under development. Pathogens. 2021;10(7):788.
- Palatnik-de-sousa CB. What would Jenner and Pasteur have done about COVID-19 Coronavirus? The urges of a vaccinologist. Front Immunol. 2020;11:2173.
- Santos N, Wigg MD. Introdução à virologia humana. 2002. Accessed 30 January 2021. https://pesquisa.bvsalud.org/portal/resource/pt/sms-2075?lang=en
- Cadeddu A. Pasteur et le choléra des poules: révision critique d’un récit historique. Hist Philos Life Sci. 1985;7:87–104.
- Berche P. Louis Pasteur, from crystals of life to vaccination. Clin Microbiol Infect. 2012;18:1–6.
- Balding B. Mandatory vaccination: why we still got to get folks to take their shots. 2006. Accessed 30 January 2021. https://dash.harvard.edu/handle/1/8852146.
- Welborn AA. Mandatory vaccinations: precedent and current laws. Ed.^(Eds) Library of Congress Washington DC Congressional Research Service; 2005
- Han S. Clinical vaccine development. Clin Exp Vaccine Res. 2015;4(1):46–53.
- Plotkin S, Robinson JM, Cunningham G, et al. The complexity and cost of vaccine manufacturing–an overview. Vaccine. 2017;35(33):4064–4071.
- Melnick JL. Current status of poliovirus infections. Clin Microbiol Rev. 1996;9(3):293–300.
- Jones SM, Feldmann H, Ströher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11(7):786–790. DOI:https://doi.org/10.1038/nm1258.
- Papaneri AB, Johnson RF, Wada J, et al. Middle East respiratory syndrome: obstacles and prospects for vaccine development. Expert Rev Vaccines. 2015;14(7):949–962.
- Cascella M, Rajnik M, Cuomo A, et al. . In: Statpearls [internet]. ; 2020. Accessed 20 February 2021. https://www.statpearls.com/ArticleLibrary/viewarticle/52171.
- Guy B, Barrere B, Malinowski C, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29(42):7229–7241.
- Joshi RS, Jagdale SS, Bansode SB, et al. Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease. J Biomol Struct Dyn. 2020;1–16. DOI:https://doi.org/10.1080/07391102.2020.1848629.
- WHO. DRAFT landscape of COVID-19 candidate vaccines; 2020 [cited 2020 Sept]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
- WHO. Global research on coronavirus disease (COVID-19). Online: WHO. 2020 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov
- O’Callaghan KP, Blatz AM, Offit PA. Developing a SARS-CoV-2 vaccine at Warp Speed. JAMA. 2020;324:437.
- Tlaxca JL, Ellis S, Remmele RL Jr. Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges. Adv Drug Deliv Rev. 2015;93:56–78.
- Pratelli A. Canine coronavirus inactivation with physical and chemical agents. Vet J. 2008;177(1):71–79.
- Jin C, Yu B, Zhang J, et al. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for the COVID-19 outbreak. BMC Infectious Diseases. 2020;21(1):1–8.
- Lundstrom K. Application of viral vectors for vaccine development with a special emphasis on COVID-19. Viruses. 2020;12(11):1324.
- Malczyk AH, Kupke A, Prüfer S, et al. A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol. 2015;89(22):11654–11667. DOI:https://doi.org/10.1128/JVI.01815-15.
- Gabitzsch ES, Xu Y, Yoshida LH, et al. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine. 2009;27(46):6394–6398.
- Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines (Basel). 2014;2(3):624–641.
- Baldo A, van den Akker E, E Bergmans H, et al. General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination. Curr Gene Ther. 2013;13(6):385–394.
- Roldão A, Mellado MCM, Castilho LR, et al. Virus-like particles in vaccine development. Expert Rev Vaccines. 2010;9(10):1149–1176.
- Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem. 2013;8(3):360–376.
- Ghanem A, Healey R, Adly FG. Current trends in separation of plasmid DNA vaccines: a review. Anal Chim Acta. 2013;760:1–15.
- Lewis PJ, Babiuk LA. DNA vaccines: a review. In: Maramorosch, Karl, Murphy, Frederick A., and Shatkin, Aaron J. Advances in virus research, 54. Academic Press: Elsevier; 1999. p. 129–188.
- Zhang C, Maruggi G, Shan H, et al. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594.
- World Health Organization (WHO). Draft landscape of COVID-19 candidate vaccines; 2020 [cited 2020 Aug 15]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
- Our World In Data. Coronavirus (COVID-19) Vaccinations. (Ed.^(Eds); 2021.
- Zimmer C. JCaS-L. Coronavirus Vaccine Tracker. The New York Times. 2020-2021.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615.
- Tanne JH. Covid-19: FDA approves Pfizer-BioNTech vaccine in record time. Ed.^(Eds) (British Medical Journal Publishing Group; 2021.
- Sanderson K. COVID vaccines protect against Delta, but their effectiveness wanes. Nature. 2021. DOI:https://doi.org/10.1038/d41586-021-02261-8
- Mahase E. Covid-19: two vaccine doses are crucial for protection against delta, study finds. Ed.^(Eds) (British Medical Journal Publishing Group; 2021.
- Mahase E. Covid vaccine could be rolled out to children by autumn. BMJ. 2021;372.
- Oliver SE, Gargano J, Marin M. The advisory committee on immunization practices’ interim recommendation for use of Moderna COVID-19 Vaccine—United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1922–1924.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384(5):403–416. DOI:https://doi.org/10.1056/NEJMoa2035389.
- Chagla Z. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19≥ 14 d after the 2nd dose. Ann Intern Med. 2021;174(3):JC28.
- Wodi AP, Ault K, Hunter P, et al. Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2021. Morbidity Mortality Weekly Rep. 2021;70(6):189.
- Johnson and Johnson. Johnson & Johnson announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 ENSEMBLE trial. (Ed.^(Eds); 2021.
- Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478.
- Jonathan Corum DG, Wee S-L, Zimmer C. Coronavirus Vaccine Tracker; 2020 [cited 2020 Aug 15]. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
- Mahase E. Covid-19: oxford researchers halt vaccine trial while adverse reaction is investigated. Ed.^(Eds) (British Medical Journal Publishing Group; 2020.
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020;397(10269):99–111.
- Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979–1993.
- Nasreen S, He S, Chung H, et al. Effectiveness of COVID-19 vaccines against variants of concern, Canada. Medrxiv. 2021.
- Wise J. Covid-19: rare immune response may cause clots after AstraZeneca vaccine, say researchers. Ed.^(Eds) (British Medical Journal Publishing Group; 2021.
- Javid YB, Bassler D, Bryant MB. Covid-19: the pros and cons of wearing masks outdoors.
- Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101.
- Torjesen I. Covid-19: risk of cerebral blood clots from disease is 10 times that from vaccination, study finds. Ed.^(Eds) (British Medical Journal Publishing Group; 2021.
- Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. bmj. 2021;373. DOI:https://doi.org/10.1136/bmj.n1114.
- Mahase E. Covid-19: astraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency. Ed.^(Eds) (British Medical Journal Publishing Group; 2021.
- Zhu F-C, Li Y-H, Guan X-H, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854.
- Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479–488.
- Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–681. DOI:https://doi.org/10.1016/S0140-6736(21)00234-8.
- Gushchin VA, Dolzhikova IV, Shchetinin AM, et al. Neutralizing activity of sera from Sputnik V-vaccinated people against variants of concern (VOC: b. 1.1. 7, B. 1.351, P. 1, B. 1.617. 2, B. 1.617. 3) and Moscow endemic SARS-CoV-2 variants. Vaccines (Basel). 2021;9(7):779.
- Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020;21(2):181–192.
- Ella R, Vadrevu KM, Jogdand H, et al. A phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 Vaccine-BBV152. medRxiv. 2020;2020:2012.2011.20210419.
- Vérez V. Informan sobre escalado productivos de candidatos vacunales cubanos. Cubadebate Inicio Noticias Salud. 2021;28.
- Szu-Min H, Liu M-C, Chen Y-H, et al. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: a large-scale double-blind, randomised, placebo-controlled phase 2 trial. medRxiv. 2021.
- ARCT ATAPI. 021 (LUNAR-COV19) phase 1/2 study results for both single shot and prime-boost regimens, and up to $220 million in additional financial commitments from Singapore| Arcturus Therapeutics, Inc. [ cited 2020 Nov 28]. cited: https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-announces-positive-interim-arct-021-lunar
- Zhang -N-N, Li X-F, Deng Y-Q, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271–1283. e1216. DOI:https://doi.org/10.1016/j.cell.2020.07.024.
- Mammen MP, Tebas P, Agnes J, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure. medRxiv. 2021.
- Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial. medRxiv. 2021.
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
- Goepfert PA, Fu B, Chabanon A-L, et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. Lancet Infect Dis. 2021;21:1257–1270.
- Hsieh S-M, Liu W-D, Huang Y-S, et al. Safety and Immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted With CpG 1018 and Aluminum Hydroxide in Healthy Adults: a Phase 1, Dose-Escalation Study. Shan-Chwen Saf Immunogenicity Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted CpG. 2021;1018.
- Taylor L. Why Cuba developed its own covid vaccine—and what happened next. bmj. 2021;374.
- Ward BJ, Gobeil P, Séguin A, et al. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat Med. 2021;27(6):1071–1078. DOI:https://doi.org/10.1038/s41591-021-01370-1.
- Gobeil P, Pillet S, Séguin A, et al. Interim report of a phase 2 randomized trial of a plant-produced virus-like particle vaccine for Covid-19 in healthy adults aged 18-64 and older adults aged 65 and older. medRxiv. 2021.
- Frontières MS. COVID-19 Vaccine Global Access (COVAX) Facility: key considerations for Gavi’s new global financing mechanism. Ed.^(Eds) (Médecins Sans Frontières Access Campaign. Recuperado; 2020.
- Phelan AL, Eccleston-Turner M, Rourke M, et al. Legal agreements: barriers and enablers to global equitable COVID-19 vaccine access. Lancet. 2020;396:800–802.
- Hsu Y-C, Wu H-C, Hsu Y-F, et al. Covid-19: global progress in developing vaccines and mechanisms for equitable distribution. Epidemiol Bull. 2020;36(16):95–95.
- Fidler DP. Vaccine nationalism’s politics. Ed.^(Eds) (American Association for the Advancement of Science; 2020.
- Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945–946.
- Rodda LB, Netland J, Shehata L, et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell. 2021;184(1):169–183. e117. DOI:https://doi.org/10.1016/j.cell.2020.11.029.
- Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. BioRxiv. 2020.
- Sewell HF, Agius RM, Kendrick D, et al. Covid-19 vaccines: delivering protective immunity. Ed.^(Eds) (British Medical Journal Publishing Group; 2020.
- Black S. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials. Expert Rev Vaccines. 2015;14(12):1543–1548.
- Le TT, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–306. DOI:https://doi.org/10.1038/d41573-020-00151-8.
- Corr P, Williams D. The pathway from idea to regulatory approval: examples for drug development. In: Conflict of interest in medical research education and practice Chapter E. Washington, DC, USA: Nat. Acad. Press; 2009.
- Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273–286.
- Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of Anti–SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085–1087. DOI:https://doi.org/10.1056/NEJMc2025179.
- He Z, Ren L, Yang J, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet. 2021;397(10279):1075–1084. DOI:https://doi.org/10.1016/S0140-6736(21)00238-5.
- Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371. DOI:https://doi.org/10.1126/science.abf4063.
- Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B. 1.351 variant. N Engl J Med. 2021;384:1885–1898.
- Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 b. 1.1. 7 lineage—United States, December 29, 2020–January 12, 2021. Morbidity Mortality Weekly Rep. 2021;70(3):95. DOI:https://doi.org/10.15585/mmwr.mm7003e2.
- Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B. 1.1. 7 in England: insights from linking epidemiological and genetic data. medRxiv. 2021. 2020.2012. 2030.20249034.
- Wise J. Covid-19: new coronavirus variant is identified in UK. Ed.^(Eds) (British Medical Journal Publishing Group; 2020.
- Reardon S. How the delta variant achieves its ultrafast spread. Nature. 2021. DOI:https://doi.org/10.1038/d41586-021-01986-w
- West AP Jr, Barnes CO, Yang Z, et al. SARS-CoV-2 lineage B. 1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape. bioRxiv. 2021.
- Tchesnokova V, Kulakesara H, Larson L, et al. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. bioRxiv. 2021. DOI:https://doi.org/10.1101/2021.02.22.432189.
- Schoch-Spana M, Brunson EK, Long R, et al. The public’s role in COVID-19 vaccination: human-centered recommendations to enhance pandemic vaccine awareness, access, and acceptance in the United States. Vaccine. 2020;39:6004–6012.
- Bhopal S, Nielsen M. Vaccine hesitancy in low-and middle-income countries: potential implications for the COVID-19 response. Arch Dis Child. 2021;106(2):113–114.
- Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397:1023–1034.
- Hossain MK, Ahmed T, Bhusal P, et al. Microneedle systems for vaccine delivery: the story so far. Expert Rev Vaccines. 2020;19:1153–1166.
- Hossain MK, Hassanzadeganroudsari M, Nurgali K, et al. Vaccine development against Methamphetamine drug addiction. Expert Rev Vaccines. 2020;19:1–10.